Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 10,406 Shares

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 10,406 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $15.89, for a total value of $165,351.34. Following the completion of the sale, the chief executive officer now directly owns 275,526 shares of the company’s stock, valued at $4,378,108.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total value of $54,948.60.

Momenta Pharmaceuticals, Inc. (MNTA) traded up $0.05 during trading hours on Monday, hitting $16.30. The stock had a trading volume of 571,269 shares, compared to its average volume of 921,225. The company has a market capitalization of $1,250.00, a price-to-earnings ratio of -20.38 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 52 week low of $11.85 and a 52 week high of $19.46.

Several analysts recently weighed in on the company. Stifel Nicolaus reissued a “hold” rating and issued a $18.00 price objective on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Zacks Investment Research lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, December 4th. BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Finally, Cowen set a $15.00 price objective on Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $15.30.

Large investors have recently bought and sold shares of the company. New York State Common Retirement Fund grew its holdings in shares of Momenta Pharmaceuticals by 9.4% during the second quarter. New York State Common Retirement Fund now owns 286,453 shares of the biotechnology company’s stock valued at $4,841,000 after purchasing an additional 24,715 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Momenta Pharmaceuticals by 12.0% during the third quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock valued at $11,224,000 after purchasing an additional 65,014 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Momenta Pharmaceuticals during the third quarter valued at approximately $1,141,000. Fisher Asset Management LLC bought a new position in shares of Momenta Pharmaceuticals during the third quarter valued at approximately $1,823,000. Finally, Candriam Luxembourg S.C.A. grew its holdings in shares of Momenta Pharmaceuticals by 15.0% during the third quarter. Candriam Luxembourg S.C.A. now owns 422,000 shares of the biotechnology company’s stock valued at $7,807,000 after purchasing an additional 55,000 shares during the last quarter. 93.01% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 10,406 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/12/momenta-pharmaceuticals-inc-mnta-ceo-craig-a-wheeler-sells-10406-shares.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply